US Patent

US8383610 — Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline

Composition of Matter · Assigned to Paratek Pharmaceuticals Inc · Expires 2030-09-23 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline forms, including salts and polymorphs, of a compound useful in treating bacterial infections and other conditions responsive to tetracycline compounds.

USPTO Abstract

Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.

Drugs covered by this patent

Patent Metadata

Patent number
US8383610
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-09-23
Drug substance claim
Yes
Drug product claim
No
Assignee
Paratek Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.